CARDIFF ONCOLOGY INC CRDF 深 滬
等待開盤 07-18 09:30:00 美东时间
4.45
+0.030
+0.68%
華盛通- 最 高4.55
- 今 開4.47
- 成交量 138.35万股
- 最 低 4.39
- 昨 收 4.42
- 總市值 2.96亿
- 52周最高 5.6395
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.01
- 委 比 20.97%
- 總股本 6652.59万
- 歷史最高 977.76
- 量 比 1.35
- 振 幅 3.62%
- 歷史最低 0.701
- 每 手 1
- 風險率 0.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ladenburg Thalmann Initiates Coverage On Cardiff Oncology with Buy Rating, Announces Price Target of $19
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Cardiff Oncology (NASDAQ:CRDF) with a Buy rating and announces Price Target of $19.
07-09 02:44
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Jefferies Initiates Coverage On Cardiff Oncology with Hold Rating, Announces Price Target of $3.5
Jefferies analyst Maury Raycroft initiates coverage on Cardiff Oncology (NASDAQ:CRDF) with a Hold rating and announces Price Target of $3.5.
06-24 20:24
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
Cardiff Oncology has appointed Roger Sidhu, MD, as Chief Medical Officer, with over 20 years of oncology experience. The company will share additional clinical data from its Phase 2 CRDF-004 trial on July 29, evaluating onvansertib for first-line RAS-mutated metastatic colorectal cancer.
06-17 20:05
Cardiff Oncology Presents Data From Investigator-Initiated Phase 1b Clinical Trial Evaluating Onvansertib In Combination With Paclitaxel In Patients With mTNBC At 2025 ASCO Annual Meeting
– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate –– The trial evaluated three doses of onvansertib in
06-03 04:11
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
Cardiff Oncology announced positive Phase 1b clinical trial results for onvansertib combined with paclitaxel in metastatic triple-negative breast cancer (mTNBC). The trial showed a 40% objective response rate at the highest dose of onvansertib, with the combination being well-tolerated and demonstrating a safe toxicity profile. The study highlights the potential of this drug combination for treating mTNBC, particularly in patients with prior chem...
06-02 20:05
SA Asks: Which oncology companies are attractive M&A targets?
Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology (NASDA...
05-31 03:00
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Raises Price Target to $18
HC Wainwright & Co. analyst Robert Burns maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and raises the price target from $17 to $18.
05-09 21:09
Cardiff Oncology Q1 EPS $(0.20) Misses $(0.19) Estimate, Sales $109.00K Beat $96.43K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 9.09 percent increase over losses of $(0.22) per share from
05-09 04:48
